Immunicum AB (IMMU) Stock Statistics & Valuation Metrics

Immunicum AB has a market cap or net worth of €250.54M. The enterprise value is kr313.66M.

Immunicum AB has 50,359,577 shares outstanding. The number of shares has decreased by -2.65% in one year.

Immunicum AB’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of Immunicum AB is -2.38. Immunicum AB’s PEG ratio is >-0.01.

In the last 12 months, Immunicum AB had revenue of 28.49M and earned -101.62M in profits. Earnings per share was -4.40.

In the last 12 months, operating cash flow was -79.67M and capital expenditures -1.84M, giving a free cash flow of -81.51M billion.

Immunicum AB pays an annual dividend of ―, resulting in a dividend yield of ―

Immunicum AB upcoming earnings date is May 6, 2025, TBA Not Confirmed.

Immunicum AB as a current ratio of 6.44, with Debt / Equity ratio of 3.39%

In the past 12 months, Immunicum AB has paid 0.00 in taxes.

Immunicum AB EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

Immunicum AB has €101.91M in cash and marketable securities with kr850.00K in debt, giving a net cash position of -€80.05M billion.

Gross margin is 52.51%, with operating margin of -353.32%, and net profit margin of -356.72%.

The average price target for Immunicum AB is ―, which is 11.43% higher than the current price. The consensus rating is ―